Canine Cancer Research: A Potential Lifeline for Dogs with Inoperable Tumors
A groundbreaking project at the University of Queensland (UQ) offers new hope for dogs facing terminal diagnoses due to inoperable or incurable cancers.
The initiative, led by Professor Rachel Allavena from UQ's School of Veterinary Sciences, aims to explore the potential of immunomodulatory drug Enzistat in treating solid tumors caused by naturally occurring cancers in dogs. These cancers include soft tissue sarcoma, mast cell tumors, and melanoma.
Enzistat, designed to target advanced cancers by activating the patient's immune system, has previously shown promising results in compassionate use trials. These trials demonstrated tumor regression and increased survival time for palliative patients with advanced, late-stage cancers, paving the way for further evaluation in a formal trial.
The research consists of two trials. The first focuses on terminal patients, aiming to prolong their lives. The second trial aims to determine if Enzistat can shrink large tumors, allowing for surgical removal. To be eligible for participation, dogs must have received a cancer diagnosis from their vet and be able to provide medical records. They must also have a predicted survival time of more than three months and be able to travel to UQ Gatton at least three times over a six-week period.
Solid tumors are a common issue in canine health, with approximately one in three dogs developing cancer in their lifetime. While canine cancers can be treated with surgery, chemotherapy, and radiotherapy, the expense and availability of these treatments often prevent dogs from receiving them. The goal of this project is to develop safe, easily applied immunotherapies that can be delivered in general practice at an affordable cost, giving each pet dog the best chance to fight its cancer.
For owners of eligible dogs, the trial can be applied for by contacting uqvets.sa@uq.edu.au. This project not only offers a potential lifeline for dogs with inoperable tumors but also paves the way for innovative immunotherapeutic approaches in veterinary medicine, which could have significant implications for the future of canine cancer treatment.
